Non-Steroidal Anti-Inflammatory Drugs
The Cmax and AUC of flurbiprofen were increased by 23% and 81%, respectively, when coadministered with Syscan compared to administration of flurbiprofen alone. Similarly, the Cmax and AUC of the pharmacologically active isomer were increased by 15% and 82%, respectively, when Syscan was coadministered with racemic ibuprofen (400 mg) compared to administration of racemic ibuprofen alone.
Although not specifically studied, Syscan has the potential to increase the systemic exposure of other non-steroidal anti-inflammatory drugs (NSAIDs) that are metabolized by CYP2C9 (e.g., naproxen, lornoxicam, meloxicam, diclofenac). Frequent monitoring for adverse events and toxicity related to NSAIDs is recommended. Adjustment of dosage of NSAIDs may be needed.
An open-label, comparative study of the efficacy and safety of DIFLUCAN (2 to 3 mg/kg/day) and oral nystatin (400,000 I.U. 4 times daily) in immunocompromised children with oropharyngeal candidiasis was conducted. Clinical and mycological response rates were higher in the children treated with Syscan.
Clinical cure at the end of treatment was reported for 86% of Syscan-treated patients compared to 46% of nystatin treated patients. Mycologically, 76% of Syscan treated patients had the infecting organism eradicated compared to 11% for nystatin treated patients.
The proportion of patients with clinical relapse 2 weeks after the end of treatment was 14% for subjects receiving DIFLUCAN and 16% for subjects receiving nystatin. At 4 weeks after the end of treatment, the percentages of patients with clinical relapse were 22% for DIFLUCAN and 23% for nystatin.
Serious Side Effects of Syscan
During concomitant treatment with Syscan (200 mg daily) and celecoxib (200 mg), the celecoxib Cmax and AUC increased by 68% and 134%, respectively. Half of the celecoxib dose may be necessary when combined with Syscan.
Voriconazole is a substrate for both CYP2C9 and CYP3A4 isoenzymes. Concurrent administration of oral Voriconazole (400 mg Q12h for 1 day, then 200 mg Q12h for 2.5 days) and oral Syscan (400 mg on Day 1, then 200 mg Q24h for 4 days) to 6 healthy male subjects resulted in an increase in Cmax and AUCτ of voriconazole by an average of 57% (90% CI: 20% to 107%) and 79% (90% CI: 40% to 128%), respectively. In a follow-on clinical study involving 8 healthy male subjects, reduced dosing and/or frequency of voriconazole and Syscan did not eliminate or diminish this effect. Concomitant administration of voriconazole and Syscan at any dose is not recommended. Close monitoring for adverse events related to voriconazole is recommended if voriconazole is used sequentially after Syscan, especially within 24 h of the last dose of Syscan. (See PRECAUTIONS.)
COMMON BRAND(S): Diflucan
GENERIC NAME(S): Syscan
Syscan is used to prevent and treat a variety of fungal and yeast infections. It belongs to a class of drugs called azole antifungals. It works by stopping the growth of certain types of fungus.
What are the uses for Diflucan (Syscan)?
- Diflucan is used for treating vaginal, oral, and esophageal fungal infections caused by Candida. It is used for treating uncomplicated, complicated, or recurrent vaginal Candida infections.
- Diflucan also may be effective in treating urinary tract infections, peritonitis, pneumonia and disseminated infections caused by Candida.
- Diflucanis used for treating cryptococcal meningitis, and prevention of Candida infections in patients treated with chemotherapy or radiation after bone marrow transplantation.